Wire · opportunities
US FDA approves Sanofi's wearable injector form of blood cancer drug
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 10 July 2026 · Fusion42 review
The FDA has approved Sarclisa Escena, a wearable subcutaneous injector form of Sanofi's blood cancer drug, replacing intravenous infusions for multiple myeloma patients and reducing oncology clinic burden.
This Wire brief sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
If you're building oncology clinic software, patient scheduling, or infusion center logistics, your market just shrank—subcutaneous wearables cut clinic visit time from hours to minutes, and systems built around chair time become obsolete. The win here is for companies selling home-based cancer monitoring, nursing support, or safety software that works outside the clinic.
◆ Coverage
1 source · 10 Jul 2026
◆ Related on Wire
◆ Topics